When assessing WL post-bariatric surgery and WR thereafter before initiation of therapy, our analysis found no significant differences between the GLP-1RAs and placebo groups, with (SMD = 0.23, 95% CI 0.36 to 0.81) for WL and SMD = 0.33, 95% CI 0.11 to 0.77) for WR, respectively (Supplementary Figs
If you are overweight or obese (with a BMI of 25 or higher) or have one or more obesity-related conditions, you may be a suitable candidate for GLP-1 therapy
Key Takeaway: Subcutaneous injections target the fatty tissue under the skin, allowing for a slow, consistent release of the medication into the bloodstream
R.QuinnJ
To fully explore the potential health benefits of durian fruit pulp extract as a functional supplement and to investigate the long-term effects of -EC as a potential neuroprotective biomarker, further in vivo studies, including animal and human trials, are recommended